Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Short-term Investments (2016 - 2025)

Arcadia Biosciences (RKDA) has disclosed Short-term Investments for 10 consecutive years, with $4.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Short-term Investments rose 80.49% year-over-year to $4.8 million, compared with a TTM value of $4.8 million through Sep 2025, up 80.49%, and an annual FY2023 reading of $5.1 million, changed N/A over the prior year.
  • Short-term Investments was $4.8 million for Q3 2025 at Arcadia Biosciences, up from $3.1 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $19.1 million in Q1 2021 and bottomed at $2.6 million in Q2 2024.
  • Average Short-term Investments over 4 years is $5.8 million, with a median of $5.0 million recorded in 2023.
  • The sharpest move saw Short-term Investments skyrocketed 526.86% in 2021, then crashed 48.24% in 2024.
  • Year by year, Short-term Investments stood at $19.1 million in 2021, then crashed by 73.16% to $5.1 million in 2023, then plummeted by 48.48% to $2.6 million in 2024, then soared by 80.49% to $4.8 million in 2025.
  • Business Quant data shows Short-term Investments for RKDA at $4.8 million in Q3 2025, $3.1 million in Q2 2025, and $2.6 million in Q3 2024.